Seven threads from the Q1 2026 release — and why the clinical milestones matter more than the income statement.
↓ scroll to read
✦ The bottom line
Beam's Q1 release is a clinical update with a financial appendix attached. Here's how management framed the quarter.
↓ the brief below
✦ Seven threads from the Q1 2026 earnings release
1
BEAM-302 has a path to pivotal.
The lead AATD program selected a 60 mg optimal biological dose, with the pivotal cohort initiating in H2 2026. The FDA has signaled an accelerated approval pathway.
2
Risto-cel landed in the New England Journal of Medicine.
Phase 1/2 BEACON data published April 1, 2026 — third-party validation of the first base-edited cell therapy. BLA submission targeted as early as year-end 2026.
3
The platform is expanding.
BEAM-304 IND filing for PKU is expected in 2026; BEAM-301 initial clinical data for GSDIa also in 2026 — both extend base editing to new genetic diseases.
4
Cash position is comfortable.
$1.2 billion of cash, equivalents, and marketable securities — including a $100M Sixth Street draw, with another $100M available. Runway extends into mid-2029.
5
R&D spend is rising.
Q1 R&D was $104.5M, up from $98.8M, as more programs entered or expanded clinical trials. G&A was $34.4M, up from $27.9M.
6
Net loss narrowed.
Net loss was $94.3M in Q1 2026, slightly improved versus $108.3M a year earlier — primarily because investment income rose with the larger cash balance.
7
Industry recognition arrived.
Beam was named to the TIME100 Most Influential Companies list, and CEO John Evans to TIME100 Health — a marker of platform credibility going mainstream.